Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
respiratory syncytial virus
Biotech
JPM26: Sanofi looks ahead to lingering US policy hurdles
Though many challenges from the Trump admin have been addressed, Sanofi still has to settle scrutiny of its vaccines and an unexpected FDA rejection.
Darren Incorvaia
Jan 14, 2026 2:28pm
Sanofi drops toddler RSV vaccine after ph. 3 heads for failure
Oct 24, 2025 7:00am
Enanta sees RSV drug fail phase 2b but finds positives
Sep 29, 2025 8:05am
Gilead blames low infection rates for ending 2 RSV trials
Jun 27, 2025 4:09am
Shionogi's RSV antiviral reduces viral load in ph. 2 adult trial
Jan 30, 2025 5:32am
Enanta RSV antiviral reduces viral load in ph. 2 pediatric trial
Dec 9, 2024 9:35am
